Poster
T-DXd
ESMO GI 2026 | July 1-4, 2026
Gastric Cancer
Real-world effectiveness and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2 positive advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJA): A multicenter prospective study in China (RECOVER Study)
Tong Xie
Poster
T-DXd
ESMO GI 2026 | July 1-4, 2026
Gastric Cancer
Trastuzumab deruxtecan in Western patients with HER2-positive advanced gastric or gastroesophageal junction cancer who progressed on or after a trastuzumab-containing regimen: Final analysis of DESTINY-Gastric02, a single-arm, phase 2 trial
Geoffrey Ku